Le Lézard
Classified in: Health, Science and technology
Subjects: SVY, TRI, FDA

Tarsius Pharma Announces FDA Acceptance of IND Application for TRS01

TEL-AVIV, Israel, Sept. 24, 2019 /PRNewswire/ -- Tarsius Pharma today announced the acceptance of its Investigational New Drug (IND) application for TRS01 by the U.S. Food and Drug Administration (FDA).

The company is developing TRS, a breakthrough, bio-inspired platform technology for the treatment of blinding ocular diseases. TRS was developed to 're-engineer' the immune system, and approaches inflammatory diseases from within the system. This IND acceptance will enable Tarsius to initiate enrollment in its planned Phase I/II clinical trial of TRS01.

The planned study is a multi-center, randomized, placebo-controlled dose-ranging study in patients with ocular inflammation following cataract surgery. This study is designed to determine the safety profile of TRS01, the recommended dose, and preliminary evaluation of the potential effect of TRS01 in ocular inflammation.

"The FDA's acceptance of our IND for TRS01 is a critical milestone for patients, as we are now one step closer to bring a new treatment that will transform the lives of people with serious blinding diseases". Said Dr. Daphne Haim-Langford, Founder and CEO, Tarsius Pharma. "This is an exciting time for us, and we look forward to embarking on our next chapter as a clinical stage company". Said Zohar Milman, Tarsius COO.

Ocular inflammatory diseases impose a significant medical and economic burden on society, affecting hundreds of million people worldwide and posing severe risks of vision loss and blindness.

In more than 50 years, corticosteroids are the most common method used to treat ocular non-infectious inflammation of any kind. Rather than treating the disease itself, however, steroids merely relieve its symptoms, and long-term use can result in devastating consequences.

The TRS Platform Technology has the potential to effectively treat a broad array of autoimmune and inflammatory ocular diseases. Untreated, these diseases can have devastating effects, and may eventually lead to blindness.

About Tarsius Pharma

Tarsius Pharma was established in 2016 and is focused on developing innovative therapeutic solutions to prevent blindness. Tarsius is backed by Sun Pharmaceuticals, a global pharmaceutical company, as well as investments by private investors and family offices. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 879598.  

For more information please contact:
Tel: +1-914-3392556

SOURCE Tarsius Pharma

These press releases may also interest you

at 06:00
iQIYI, Inc. ("iQIYI" or the "Company"), an innovative market-leading online entertainment service in China, recently announced upcoming releases of 60 major drama series and variety shows at its iJOY Conference (the "Conference") held in Shanghai....

at 05:00
This year's topic is Hack the Crisis: Business Tips for Post-Covid Era. The online event is to happen on July 23, 2020. The event will gather ride-hailing entrepreneurs, stakeholders, and experts from around the globe. Speakers will share insights...

at 03:00
MedAlliance has announced enrollment of the first patient in its study of SELUTION SLRtm 014 DEB for the treatment of In-Stent Restenosis (ISR). This is the first DEB accepted by the FDA for its 'Breakthrough Program'. The SELUTION SLR (Sustained...

10 jui 2020
Syniti, a global data solution provider, today announced a continued commitment to accelerating customers' digital transformation with its Global Alliance Partners. In the first six months of 2020, Syniti's revenue with Alliance Partners grew more...

10 jui 2020
Growatt, one of the world's top 5 three-phase string inverter suppliers according to IHS Markit, introduces MAC series of its X generation inverters for three-phase solar PV market in Brazil. The new inverter series provide flexibility to meet the...

10 jui 2020
Technavio has been monitoring the adaptive learning software market and it is poised to grow by $ 384.99 mn during 2020-2024, progressing at a CAGR of over 11% during the forecast period. The report offers an up-to-date analysis regarding the current...

News published on 24 september 2019 at 10:00 and distributed by: